Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus

Mazalovska, Milena; Kouokam, J. Calvin

doi:10.3390/v12080826

Cited by 13 publications

(9 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hecolin® has shown a good safety profile and 100% efficacy in humans. Studies are currently underway to assess vaccine safety and efficacy in high-risk groups for potential global use, as recommended by the WHO [168].…”

Section: Hepatitis E Virus (Hev) Vaccinementioning

confidence: 99%

Virus-like particle vaccinology, from bench to bedside

Mohsen

Bachmann

2022

Cell Mol Immunol

View full text Add to dashboard Cite

Virus-like particles (VLPs) have become key tools in biology, medicine and even engineering. After their initial use to resolve viral structures at the atomic level, VLPs were rapidly harnessed to develop antiviral vaccines followed by their use as display platforms to generate any kind of vaccine. Most recently, VLPs have been employed as nanomachines to deliver pharmaceutically active products to specific sites and into specific cells in the body. Here, we focus on the use of VLPs for the development of vaccines with broad fields of indications ranging from classical vaccines against viruses to therapeutic vaccines against chronic inflammation, pain, allergy and cancer. In this review, we take a walk through time, starting with the latest developments in experimental preclinical VLP-based vaccines and ending with marketed vaccines, which earn billions of dollars every year, paving the way for the next wave of prophylactic and therapeutic vaccines already visible on the horizon.

show abstract

Section: Hepatitis E Virus (Hev) Vaccinementioning

confidence: 99%

Virus-like particle vaccinology, from bench to bedside

Mohsen

Bachmann

2022

Cell Mol Immunol

View full text Add to dashboard Cite

show abstract

“…As we have emphasized, BEVS is widely used to produce VSPs (Mazalovska and Kouokam 2020). When one or more of these VSPs are coexpressed, they can self-assemble forming nonreplicative and nonpathogenic particles known as virus-like particles (VLPs).…”

Section: Baculoviruses As Tools For the Control And Diagnosis Of Emerging Human Infectious Diseasesmentioning

confidence: 99%

Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies

Targovnik

Simonin

Callum

et al. 2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Baculoviruses are insect pathogens widely used as biotechnological tools in different fields of life sciences and technologies. The particular biology of these entities (biosafety viruses 1; large circular double-stranded DNA genomes, infective per se; generally of narrow host range on insect larvae; many of the latter being pests in agriculture) and the availability of molecular-biology procedures (e.g., genetic engineering to edit their genomes) and cellular resources (availability of cell lines that grow under in vitro culture conditions) have enabled the application of baculoviruses as active ingredients in pest control, as systems for the expression of recombinant proteins (Baculovirus Expression Vector Systems-BEVS) and as viral vectors for gene delivery in mammals or to display antigenic proteins (Baculoviruses applied on mammals-BacMam). Accordingly, BEVS and BacMam technologies have been introduced in academia because of their availability as commercial systems and ease of use and have also reached the human pharmaceutical industry, as incomparable tools in the development of biological products such as diagnostic kits, vaccines, protein therapies, and-though still in the conceptual stage involving animal models-gene therapies. Among all the baculovirus species, the Autographa californica multiple nucleopolyhedrovirus has been the most highly exploited in the above utilities for the human-biotechnology field. This review highlights the main achievements (in their different stages of development) of the use of BEVS and BacMam technologies for the generation of products for infectious and noninfectious human diseases. Key points• Baculoviruses can assist as biotechnological tools in human health problems.• Vaccines and diagnosis reagents produced in the baculovirus platform are described.• The use of recombinant baculovirus for gene therapy-based treatment is reviewed.

show abstract

“…The major anti-HEV antibody responses are against epitopes located at 459–606 aa of HEV ORF2 [ 18 ] and are mainly conformational [ 19 ]. Full-length and partially truncated versions of the capsid protein have been expressed in different systems (bacteria, yeast, insect cells, mammalian cells, and plants) to generate virus-like particles (VLPs) for vaccine design [ 20 , 21 , 22 , 23 , 24 , 25 , 26 ]. However, there can be issues of yield and product heterogeneity using this approach and alternatives are required.…”

Section: Introductionmentioning

confidence: 99%

Efficient Production of Chimeric Hepatitis B Virus-Like Particles Bearing an Epitope of Hepatitis E Virus Capsid by Transient Expression in Nicotiana benthamiana

Zahmanova

Mazalovska

Takova

et al. 2021

Life

Self Cite

View full text Add to dashboard Cite

The core antigen of hepatitis B virus (HBcAg) is capable of self-assembly into virus-like particles (VLPs) when expressed in a number of heterologous systems. Such VLPs are potential carriers of foreign antigenic sequences for vaccine design. In this study, we evaluated the production of chimeric HBcAg VLPs presenting a foreign epitope on their surface, the 551–607 amino acids (aa) immunological epitope of the ORF2 capsid protein of hepatitis E virus. A chimeric construct was made by the insertion of 56 aa into the immunodominant loop of the HBcAg. The sequences encoding the chimera were inserted into the pEAQ-HT vector and infiltrated into Nicotiana benthamiana leaves. The plant-expressed chimeric HBcHEV ORF2 551–607 protein was recognized by an anti-HBcAg mAb and anti-HEV IgG positive swine serum. Electron microscopy showed that plant-produced chimeric protein spontaneously assembled into “knobbly” ~34 nm diameter VLPs. This study shows that HBcAg is a promising carrier platform for the neutralizing epitopes of hepatitis E virus (HEV) and the chimeric HBcAg/HEV VLPs could be a candidate for a bivalent vaccine.

show abstract

Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus

Cited by 13 publications

References 131 publications

Virus-like particle vaccinology, from bench to bedside

Virus-like particle vaccinology, from bench to bedside

Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies

Efficient Production of Chimeric Hepatitis B Virus-Like Particles Bearing an Epitope of Hepatitis E Virus Capsid by Transient Expression in Nicotiana benthamiana

Contact Info

Product

Resources

About